Renalytix Share Discussion Threads

[trickydicky1] 14/1/2021 08:59

My key question to James in the IPO roadshow was whether, in the highly unlikely event that the occasion arose, he had the balls to ride the unicorn up to a decacorn. I remain unconvinced. I fear he has been tainted by the Mills ‘sell up’ crowd. ;)

[mr roper] 14/1/2021 08:58

Good point on the deployments, 74tom. Even the CEO sounded amazed. It was only 5 weeks ago on the Stifel call he said he hoped to have 3 done this year but the Da Vita partnership has changed this completely and now, as you say, he expects 5 or 6.

Remarkable progress here

[74tom] 14/1/2021 08:55

Also 41 mins, 5 or 6 deployments prior to 30th June... wow!

[wan] 14/1/2021 08:47

Not sure where $24 come from, but Nasdaq data for yesterday close shows $22.50 -

[digger18] 14/1/2021 08:44

I couldn’t access the presentation last night on their website. Does anyone know when general access will be available, or could provide a link. Thank you

[videologic] 14/1/2021 08:37

No, finished up at $24 , a 39% rise.

[mr roper] 14/1/2021 08:34

Some numbers from yesterday’s call that I’m still struggling to get my head around.
50% of all Americans are obese.
1/3 of all Americans are clinically obese.
50% of kidney patients are put on dialysis via a trip to the emergency room.

The market for early stage diagnosis via RenalytixAI is monumental.

The MCIT finalisation basically means that upon fda approval RenalytixAI gains national exposure immediately. As the CEO stated, it’s like being in at the start of the gold rush.

[mr roper] 14/1/2021 08:25

Same,mf. If you’ve not listened to yesterdays call yet put it on your list for the weekend.

[donald pond] 14/1/2021 08:16

Bought some first thing too, bonkers price action

[mr roper] 14/1/2021 08:14

If they execute to plan we could easily see a mkt cap of 10bn usd+ in 3-5 years.

Still in the foothills here but the US at least seems to be waking up.

[lottsgold] 14/1/2021 08:12

Yep grabbed some more!

[wan] 14/1/2021 08:11

It should be music to investors ears, when the CEO can effectively and clearly state not only the 'initial' very large target market, but importantly why there are no direct competitors and effectively communicate and demonstrate the 'very high' barriers to entry.

[wan] 14/1/2021 04:39

Renalytix finished up over 18% at $20.50 on Nasdaq. I make that equivalent to £8.25 per share.


During the presentation Co-founder and CEO James McCullough also referred to Kantaro's antibody test as important testing technology and that they are making great strides to get this test out (EKF also gets mentioned in this regard). He states that quantitative antibody testing will be a significant issue in 2021 and 'beyond'.

The following article adds more colour and some transparency regarding the FDA approval, which looks set to change, but EKF can already distribute in Europe on the basis of a fully quantitative test -

Next-gen antibody tests promise more answers to Covid-19 questions

The new tests can open a window into the duration of immunity and to the antibody levels needed to sustain it. But first, a universal standard is needed to ensure results are comparable between tests.
By JOEL BERG
11th January 2021

“There’s still a lot to be learned,” said Michael Haydock, a senior director at Informa Pharma Intelligence in London.

For example, he said, researchers don’t know if there is a threshold number of antibodies a person needs to maintain immunity, Haydock said. Quantitative tests could help pinpoint a threshold and track whether antibodies fall below it, potentially necessitating a booster vaccine.

“Measuring that is going to be very important,” Haydock said in a phone interview. Tests also may be able to quantify differences in immune response based on age, race and other factors.

In addition, quantitative tests can be used to assess people who have recovered from Covid-19 and want to donate plasma for use in convalescent plasma therapy, a treatment for the virus. Researchers also may be interested in understanding the response to Covid-19 vaccines among those who are already on therapies that modify their immune systems.

“That’s the nature of this pandemic, that you’re trying to move forward when you have more questions than you have answers. Antibody testing can help answer those questions,” said Sara Barrington, chief commercial officer for Kantaro Biosciences.

The New York-based company offers a quantitative antibody test for Covid-19 using technology developed at Mount Sinai Health System early in the pandemic. Kantaro is a joint venture between Mount Sinai and RenalytixAI, a diagnostics company based in the United Kingdom.

Complicating the issue is the lack of an agreed-upon standard for measuring antibodies. However, clarity is on the horizon.

The World Health Organization is expected to set standards soon, Barrington said in a phone interview.

“With an international standard, you’d be able to compare the results across different tests,” said Erik Lium, Kantaro’s chairman and the chief commercial innovation officer at Mount Sinai.

In November, the Food and Drug Administration approved Kantaro’s test for emergency use. But the approval comes with a qualification: the test, called COVID-SeroKlir, is considered semi-quantitative.

The FDA appears to be waiting for the international standard to be set before declaring tests fully quantitative, Barrington said. However, European regulators are not waiting. They cleared COVID-SeroKlir for use as a fully quantitative test.

Full story -

[mr roper] 13/1/2021 21:26

The presentation was exceptional and the q and a very interesting. Good to see the US market leading the way.

[donald pond] 13/1/2021 21:23

Huge volume in US, equivalent of 700,000 shares today compared to 87,000 in UK

[busterdog2] 13/1/2021 21:06

£7.50p equivalence to Nasdaq price.

[lottsgold] 13/1/2021 19:52

Only have a small stake here but looking like we've caught the eye of the NASDAQ bunch. Long may it continue!

[mr roper] 13/1/2021 19:37

THrough $22 now. +27%

[mr roper] 13/1/2021 19:26

$rnlx absolutely flying on Nasdaq. Broke the 20 buck barrier and now up 18%. Hoping for similar here tomorrow. A break and run at 800p would be great.

[mr roper] 13/1/2021 16:54

$rnlx at$19.50 I make that approx 720p

[mr roper] 13/1/2021 16:25

Breaking out Stateside. When the CEO equates MCIT as being in at the start of the gold rush you can’t help but think a lot of folk have not cottoned on to the opportunity here. Absolutely huge.

[wan] 13/1/2021 15:55

I concur, very encouraging indeed, and that's to say the least!